JP2016501234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501234A5 JP2016501234A5 JP2015545523A JP2015545523A JP2016501234A5 JP 2016501234 A5 JP2016501234 A5 JP 2016501234A5 JP 2015545523 A JP2015545523 A JP 2015545523A JP 2015545523 A JP2015545523 A JP 2015545523A JP 2016501234 A5 JP2016501234 A5 JP 2016501234A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- her2
- composition according
- trastuzumab
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 8
- 229960000575 trastuzumab Drugs 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 229960004679 doxorubicin Drugs 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732736P | 2012-12-03 | 2012-12-03 | |
| US61/732,736 | 2012-12-03 | ||
| US201361810254P | 2013-04-09 | 2013-04-09 | |
| US61/810,254 | 2013-04-09 | ||
| PCT/US2013/072941 WO2014089127A1 (en) | 2012-12-03 | 2013-12-03 | Combination therapy for treating her2-positive cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501234A JP2016501234A (ja) | 2016-01-18 |
| JP2016501234A5 true JP2016501234A5 (enExample) | 2017-02-02 |
Family
ID=50883946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545523A Pending JP2016501234A (ja) | 2012-12-03 | 2013-12-03 | Ｈｅｒ２陽性癌を処置するための併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9913901B2 (enExample) |
| EP (1) | EP2925361A4 (enExample) |
| JP (1) | JP2016501234A (enExample) |
| KR (1) | KR20150091116A (enExample) |
| CN (2) | CN105050619A (enExample) |
| AU (1) | AU2013355337B2 (enExample) |
| CA (1) | CA2892859A1 (enExample) |
| HK (1) | HK1214955A1 (enExample) |
| IL (1) | IL239031A0 (enExample) |
| MX (1) | MX2015006931A (enExample) |
| SG (1) | SG11201504293WA (enExample) |
| WO (1) | WO2014089127A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089127A1 (en) | 2012-12-03 | 2014-06-12 | Merrimack Pharmaceuticals, Inc. | Combination therapy for treating her2-positive cancers |
| ES2964893T3 (es) * | 2013-07-17 | 2024-04-10 | Found Medicine Inc | Procedimientos de tratamiento de carcinomas uroteliales |
| US20160045596A1 (en) * | 2014-08-05 | 2016-02-18 | Merrimack Pharmaceuticals, Inc. | Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies |
| WO2017136770A1 (en) * | 2016-02-05 | 2017-08-10 | Merrimack Pharmaceuticals, Inc. | Treatment of her2-intermediate cancer |
| CN110709419B (zh) * | 2017-01-06 | 2023-11-28 | 博奥信生物技术（南京）有限公司 | Erbb2抗体及其用途 |
| CN115957321A (zh) * | 2023-03-03 | 2023-04-14 | 盛禾(中国)生物制药有限公司 | 一种抗her2抗体在制备治疗癌症的药物中的用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US20050084524A1 (en) * | 1998-09-30 | 2005-04-21 | Alza Corporation | Method for potentiating activity of a chemotherapeutic drug |
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| GB0326486D0 (en) | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| US7674456B2 (en) * | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| UA94899C2 (ru) * | 2005-01-21 | 2011-06-25 | Дженентек, Инк. | Фиксированное дозирование антител к her |
| AU2006239973A1 (en) | 2005-04-22 | 2006-11-02 | Alza Corporation | Immunoliposome composition for targeting to a HER2 cell receptor |
| US7976852B2 (en) * | 2005-04-26 | 2011-07-12 | Eisai R&D Management Co., Ltd. | Compositions and methods for cancer immunotherapy |
| PL2129396T3 (pl) | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| CN101878229A (zh) | 2007-09-28 | 2010-11-03 | 巴塞尔大学医院 | 用于治疗癌症的免疫脂质体 |
| EA022201B1 (ru) | 2008-04-11 | 2015-11-30 | Мерримак Фармасьютикалз, Инк. | Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| CN103327983A (zh) * | 2010-12-06 | 2013-09-25 | 梅里麦克制药股份有限公司 | 在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药 |
| US20120231066A1 (en) * | 2011-01-24 | 2012-09-13 | Henry John Smith | Multi-drug liposomes to treat tumors |
| WO2014089127A1 (en) | 2012-12-03 | 2014-06-12 | Merrimack Pharmaceuticals, Inc. | Combination therapy for treating her2-positive cancers |
-
2013
- 2013-12-03 WO PCT/US2013/072941 patent/WO2014089127A1/en not_active Ceased
- 2013-12-03 MX MX2015006931A patent/MX2015006931A/es unknown
- 2013-12-03 US US14/650,250 patent/US9913901B2/en not_active Expired - Fee Related
- 2013-12-03 SG SG11201504293WA patent/SG11201504293WA/en unknown
- 2013-12-03 JP JP2015545523A patent/JP2016501234A/ja active Pending
- 2013-12-03 CN CN201380070261.4A patent/CN105050619A/zh active Pending
- 2013-12-03 KR KR1020157017006A patent/KR20150091116A/ko not_active Withdrawn
- 2013-12-03 CN CN201710112540.2A patent/CN107412163A/zh active Pending
- 2013-12-03 AU AU2013355337A patent/AU2013355337B2/en not_active Expired - Fee Related
- 2013-12-03 EP EP13860427.7A patent/EP2925361A4/en not_active Withdrawn
- 2013-12-03 CA CA2892859A patent/CA2892859A1/en not_active Abandoned
- 2013-12-03 HK HK16102942.7A patent/HK1214955A1/zh unknown
-
2015
- 2015-05-27 IL IL239031A patent/IL239031A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501234A5 (enExample) | ||
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| PH12012502399A1 (en) | Combination therapy methods for treating proliferative diseases | |
| MX2014004548A (es) | Metodos para tratar pacientes pediatricos usando dexmedetomidina. | |
| AR068532A1 (es) | Inhibicion de angiogenesis | |
| NZ703047A (en) | Methods of enhancing drug delivery and effectiveness of therapeutic agents | |
| AR059982A1 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| MX2020003719A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| WO2011091305A3 (en) | Inhibition of axl signaling in anti-metastatic therapy | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| JP2012193216A5 (enExample) | ||
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| Long et al. | Single-arm, multi-centre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| JP2016519107A5 (enExample) | ||
| MX2020007130A (es) | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. | |
| WO2014160216A3 (en) | Dual targeting anticancer agents | |
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| MX2015015434A (es) | Corroles dirigidas para toxicidad tumoral y rm. | |
| PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |